Table 2.

Ongoing trials on medical therapies for the treatment of adenomyosis

NCT number	Conditions	Study design	Interventions	Outcome measures
NCT05151016	Patients with adenomyosis	Randomized interventional study	Study Group: mifepristone 10 mg oral tablets, daily for 24 weeks	Change from baseline in pain on the visual analogue scale at week 24
			Control Group: Triptorelin Acetate 3.75 mg subcutaneous injection, every 28 days for 24 weeks	Pictorial blood loss assessment chart
				Change from baseline in uterine size at week 24
				Change from baseline in hemoglobin at week 24
				Change from baseline in CA125 at week 24
NCT03654144	Patients with adenomyosis	Randomized interventional study	Study Group: Dienogest oral tablet	Mean pain score
			Control Group: Combined Oral Contraceptive
NCT03421639	Patients with adenomyosis Patients who underwent recurrent implantation failure	Randomized interventional study	Study group: oral anastrazole 1 mg/day oral tablet plus leuprolide 3.75 mg/monthly for 12 weeks	Pregnancy after embryo transfer Uterine volume reduction
			Control Group: leuprolide acetate 3.75 mg subcutaneous injection, every 28 days for 12 weeks
NCT03037944	Patients with adenomyosis	Randomized interventional study	Group A: LNG- IUS 60 mg	Measurement of pain by an appropriate pain measurement score
			Group B: ethinyl estradiol 0.03 mg plus drospirenone 3 mg oral tablets, daily for 24 weeks.	Number of bleeding days
NCT02556411	Patients with adenomyosis	Randomized interventional study	Study group: LNG 0.10 mg plus ethinylestradiol 0.02 mg oral tablets, daily	Change of pelvic pain as measured by visual analogue scale Quality of sexual life
			Control group: LNG-IUS 13.5 mg.

LNG-IUS levonorgestrel intrauterine system